Cannabinoids and glaucoma.

Br J Ophthalmol

Department of Ophthalmology, Aberdeen Royal Infirmary, University of Aberdeen, UK.

Published: May 2004

Glaucoma is one of the leading causes of blindness in the world. In spite of the diverse therapeutic possibilities, new and better treatments for glaucoma are highly desirable. Cannabinoids effectively lower the intraocular pressure (IOP) and have neuroprotective actions. Thus, they could potentially be useful in the treatment of glaucoma. The purpose of this article is to provide the reader with an overview of the latest achievements in research into the potential use of cannabinoids for glaucoma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1772142PMC
http://dx.doi.org/10.1136/bjo.2003.032250DOI Listing

Publication Analysis

Top Keywords

cannabinoids glaucoma
8
glaucoma
4
glaucoma glaucoma
4
glaucoma leading
4
leading blindness
4
blindness spite
4
spite diverse
4
diverse therapeutic
4
therapeutic possibilities
4
possibilities better
4

Similar Publications

Cannabis is the most used drug worldwide with an estimated 219 million users. This narrative review aims to explore the adverse effects and therapeutic applications of cannabis and cannabinoids on the eye, given its growing clinical and non-clinical uses. The current literature reports several adverse ocular effects of cannabis and cannabinoids, including eyelid tremor, ptosis, reduced corneal endothelial cell density, dry eyes, red eyes, and neuro-retinal dysfunction.

View Article and Find Full Text PDF

Cannabinoids for the Treatment of Glaucoma: A Review.

Med Cannabis Cannabinoids

September 2024

Department of Pharmacology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India.

Background: Glaucoma is an ocular disease with significant health burden. Despite the availability of many antiglaucoma drugs, a significant proportion of patients may experience worsening of the disease. Hence, there is a need for newer antiglaucoma drugs.

View Article and Find Full Text PDF

Growing interest but limited evidence on the usefulness of cannabidiol in treating ophthalmic disease in dogs: a review.

J Am Vet Med Assoc

December 2024

Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO.

The 2 most known cannabinoids are Δ9-tetrahydrocannabidiol (THC) and cannabidiol (CBD). Both chemicals are extracted from the cannabis plant but can also be synthetically produced. Δ9-Tetrahydrocannabidiol is extracted from the subspecies of the cannabis plant known as the marijuana plant, which contains a high concentration of THC (0.

View Article and Find Full Text PDF

Marijuana has been used by humans for thousands of years for both medicinal and recreational purposes. This included the treatment of pain, inflammation, seizures, and nausea. In the 1960s, the structure of the principal psychoactive ingredient Δ9-tetrahydrocannabinol was determined, and over the next few decades, two cannabinoid receptors were characterized along with the human endocannabinoid system and what it affects.

View Article and Find Full Text PDF
Article Synopsis
  • Cannabidiol, a compound derived from the Cannabis plant, has promising pharmacological effects, particularly when used topically, and is linked to fewer adverse events compared to other cannabinoids.
  • The study conducts a scoping review to analyze the efficacy of topical cannabidiol through in vivo models, guided by the Joanna Briggs Institute's methodology and established inclusion criteria.
  • Though further research is required to determine optimal dosages, cannabidiol shows potential in treating various health issues, including glaucoma, atopic dermatitis, epidermolysis bullosa, and pyoderma gangrenosum.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!